Literature DB >> 33582392

Changing trends in hepatocellular carcinoma management: Results from a nationwide database in the last decade.

Christophe Cassinotto1, Erika Nogue2, Mathieu Morell3, Fabrizio Panaro4, Nicolas Molinari5, Boris Guiu6.   

Abstract

OBJECTIVE: The therapeutic strategies for hepatocellular carcinoma (HCC) have greatly expanded in recent years. However, the actual usage of each of these treatments in clinical routine remains unknown. Here, we analysed the distribution and changes of the main surgical and radiological therapeutic procedures nationwide during the last decade.
METHODS: Retrospectively, analysis of the data on all >18-year-old patients with a diagnosis of HCC identified in the French Program for the Medicalization of Information Systems database that contains all discharge summaries from all French hospitals. The number and percentage of the therapeutic procedures performed from January 2010 to December 2019 were extracted.
RESULTS: A total of 68,416 therapeutic procedures were performed in 34,000 HCC patients. Whereas HCC incidence remained stable, the annual number of procedures frankly increased over the decade (from 4267 to 8042). Trans-arterial chemoembolization was the most frequently performed technical procedure, with a double-digit annual growth from 2010 (n = 1932) to 2015 (n = 4085), before stabilization from 2016. Selective internal radiation therapy displayed the highest increase in the decade (+475%). Among curative treatments, the annual number of percutaneous tumour ablations more than doubled in 10 years, till representing 64% of curative treatments in cirrhotic patients in 2019. Surgical tumour resections showed a 1.5-fold increase in 10 years, due to the great increase in minimally invasive approaches, whereas the proportion of open resection progressively decreased.
CONCLUSION: Minimally invasive procedures have gained major importance in HCC management during the last decade. Percutaneous thermal ablation has emerged as the first curative treatment performed for patients with HCC.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epidemiology; Hepatocellular carcinoma; Interventional radiology; Liver cirrhosis; Oncology; Surgery; Thermal ablation

Year:  2021        PMID: 33582392     DOI: 10.1016/j.ejca.2021.01.009

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  2 in total

Review 1.  TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC.

Authors:  Boris Guiu; Etienne Garin; Carole Allimant; Julien Edeline; Riad Salem
Journal:  Cardiovasc Intervent Radiol       Date:  2022-02-11       Impact factor: 2.740

2.  Non-transplantable recurrence after percutaneous thermal ablation of ≤3-cm HCC: Predictors and implications for treatment allocation.

Authors:  Cecilia Gozzo; Margaux Hermida; Astrid Herrero; Fabrizio Panaro; Christophe Cassinotto; Azhar Meerun Mohamad; Eric Assenat; Chloé Guillot; Carole Allimant; Valentina Schembri; Antonio Basile; Sébastien Dharancy; José Ursic-Bedoya; Boris Guiu
Journal:  Hepatol Commun       Date:  2022-08-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.